Core Viewpoint - The approval of PB-119 by the National Medical Products Administration of China is a significant milestone for the company, leading to a notable increase in its stock price [1]. Group 1: Company Developments - The company, Paig BioPharma-B (02565), saw its stock price rise by nearly 15%, reaching HKD 72.7, with a trading volume of HKD 1.1269 million following the announcement [1]. - PB-119, the company's core product, is a new generation long-acting GLP-1 receptor agonist that requires weekly administration [1]. - PB-119 has been recognized as a Class 1 new drug by the National Major Science and Technology Projects for its innovative drug creation [1]. Group 2: Product Efficacy - Clinical studies (Phase I to III) have shown that PB-119 achieves an optimal balance between effective blood sugar control and good tolerability [1]. - The product offers an efficient and safe treatment option for patients with type 2 diabetes in China, significantly improving β-cell function [1]. - PB-119 also manages blood pressure, blood lipids, and body weight, providing comprehensive benefits for patients [1].
港股异动 | 派格生物医药-B(02565)高开近15% 核心产品PB-119新药上市申请获批